NCT03753659 2026-03-23
IMMULAB - Immunotherapy With Pembrolizumab in Combination With Local Ablation in Hepatocellular Carcinoma (HCC)
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2 Completed
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Washington University School of Medicine
National Institutes of Health Clinical Center (CC)
University of Utah